StemSight

StemSight is a spin-out from Professor Heli Skottman’s lab in Tampere University, Finland. StemSight develops allogeneic iPS cell-based therapies for corneal blindness. StemSight’s first product is aimed at the rare disease called limbal stem cell deficiency, aiming to restore vision in these severely blinded patients.

Therapeutic Developer